Compare Galaxy Digital Inc. Class A Common Stock (GLXY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Galaxy Digital Inc. Class A Common Stock vs Organon & Co. Common Stock — how do they compare? Galaxy Digital Inc. Class A Common Stock trades at $17.36 (market cap $3.48B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Galaxy Digital Inc. Class A Common Stock and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Galaxy Digital Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Galaxy Digital Inc. Class A Common Stock for 2 Days and Organon & Co. Common Stock for 0 Days on average.
| GLXY | OGN | |
|---|---|---|
Market Cap | $3.48B | $3.61B |
Volume | 9,375,439 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $42.86 | $13.81 |
52-Week Low | $16.84 | $5.70 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $5.93B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Galaxy Digital (GLXY) trades at $19.71, down 0.81% with bearish technical signals but strong analyst support. The company reported Q2 2026 EPS of -$0.09, beating expectations, though revenue declined to $57.4B in 2026 with a net loss of -$315M. Recent news includes a Citigroup upgrade to Buy and upcoming Q3 earnings on October 27, 2026.
Despite current losses, analyst consensus is bullish with an $38.20 price target (81.8% Buy ratings). Key risks include negative profit margins and cash flow challenges, but institutional buying and strategic partnerships provide upside potential if earnings improve.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Galaxy Digital Inc. Class A Common Stock
Galaxy provides digital-asset financial services and data center infrastructure. Its digital-assets business includes trading, asset management, investment banking, staking, tokenization, and custody technology.
Read more on GLXY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
